Department of Medical Physiology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Blood Adv. 2020 Nov 10;4(21):5501-5511. doi: 10.1182/bloodadvances.2020002923.
Our previous real-time imaging studies directly demonstrated the spatiotemporal regulation of clot formation and lysis by activated platelets. In addition to their procoagulant functions, platelets enhanced profibrinolytic potential by augmenting the accumulation of tissue-type plasminogen activator (tPA) and plasminogen, in vivo in a murine microthrombus model, and in vitro in a platelet-containing plasma clot model. To clarify the role of thrombin-activatable fibrinolysis inhibitor (TAFI), which regulates coagulation-dependent anti-fibrinolytic potential, we analyzed tPA-induced clot lysis times in platelet-containing plasma. Platelets prolonged clot lysis times in a concentration-dependent manner, which were successfully abolished by a thrombomodulin-neutralizing antibody or an activated TAFI inhibitor (TAFIaI). The results obtained using TAFI- or factor XIII-deficient plasma suggested that TAFI in plasma, but not in platelets, was essential for this prolongation, though its cross-linkage with fibrin was not necessary. Confocal laser scanning microscopy revealed that fluorescence-labeled plasminogen accumulated on activated platelet surfaces and propagated to the periphery, similar to the propagation of fibrinolysis. Plasminogen accumulation and propagation were both enhanced by TAFIaI, but only accumulation was enhanced by thrombomodulin-neutralizing antibody. Labeled TAFI also accumulated on both fibrin fibers and activated platelet surfaces, which were Lys-binding-site-dependent and Lys-binding-site-independent, respectively. Finally, TAFIaI significantly prolonged the occlusion times of tPA-containing whole blood in a microchip-based flow chamber system, suggesting that TAFI attenuated the tPA-dependent prolongation of clot formation under flow. Thus, activated platelet surfaces are targeted by plasma TAFI, to attenuate plasminogen accumulation and fibrinolysis, which may contribute to thrombogenicity under flow.
我们之前的实时成像研究直接证明了激活的血小板对血栓形成和溶解的时空调节。除了促凝功能外,血小板还通过增加组织型纤溶酶原激活物(tPA)和纤溶酶原的积累,增强纤维蛋白溶解潜能,在体内的小鼠微血栓模型中和在含血小板的血浆凝块模型中都有增强纤维蛋白溶解潜能的作用。为了阐明调节凝血依赖性抗纤溶潜能的凝血酶激活的纤溶抑制物(TAFI)的作用,我们分析了含血小板的血浆中 tPA 诱导的血栓溶解时间。血小板以浓度依赖的方式延长了血栓溶解时间,这种作用可被血栓调节蛋白中和抗体或活化的 TAFI 抑制剂(TAFIaI)成功消除。使用 TAFI 或因子 XIII 缺陷型血浆获得的结果表明,血浆中的 TAFI 而不是血小板中的 TAFI 对于这种延长是必需的,尽管其与纤维蛋白的交联不是必需的。共焦激光扫描显微镜显示,荧光标记的纤溶酶原在激活的血小板表面聚集并向周围扩散,类似于纤维蛋白溶解的扩散。TAFIaI 增强了纤溶酶原的聚集和扩散,但只有血栓调节蛋白中和抗体增强了纤溶酶原的聚集。标记的 TAFI 也在纤维蛋白纤维和激活的血小板表面上聚集,这分别是赖氨酸结合位点依赖性和赖氨酸结合位点非依赖性的。最后,TAFIaI 在基于微芯片的流动腔系统中显著延长了含有 tPA 的全血的闭塞时间,这表明 TAFI 减弱了 tPA 依赖性的血栓形成的延长在流动条件下。因此,血浆 TAFI 靶向激活的血小板表面,以减弱纤溶酶原的聚集和纤维蛋白溶解,这可能有助于在流动条件下的血栓形成。